Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Bendamustine and Rituximab in Elderly Mantle Cell Lymphoma
NCT00963534Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- Sep 2009
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in mantle cell lymphoma (MCL), sponsored by Skåne University Hospital. Primary endpoints: Maximally Tolerated Dose of Lenalidomide and Progression Free Survival at 2 years. Started Sep 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00963534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00963534.